Table 1 Baseline characteristics of the model development and test sets.

From: Circulating Microbiota-Based Metagenomic Signature for Detection of Hepatocellular Carcinoma

  Development set p Test set p
HCC (n = 79) Cirrhosis (n = 83) Healthy controls (n = 201) HCC (n = 79) Cirrhosis (n = 83) Healthy controls (n = 201)
Age, years 58.6 ± 9.6 57.1 ± 10.7 57.6 ± 10.4 0.61 58.8 ± 10.3 56.5 ± 9.9 56.6 ± 10.0 0.22
Male 58 (73.4%) 62 (74.7%) 119 (71.2%) 0.83 64 (81.0%) 58 (70.0%) 127 (75.1%) 0.26
Etiology of liver disease
Viral 73 (92.4%) 54 (65.1%) <0.001 70 (88.6%) 71 (85.5%) 0.73
Non-viral 6 (8.6%) 29 (34.9%)   9 (11.3%) 12 (14.5%)  
Liver function
Compensated 71 (89.9%) 56 (67.5%) 0.001 72 (91.1%) 62 (73.5%) 0.006
Decompensated 8 (10.1%) 27 (32.5%)   7 (8.9%) 22 (26.5%)  
α-fetoprotein, ng/mL, median (IQR) 4.8 (2.6–7.4) 11.1 (4.6–71.2) <0.001 3.7 (2.2–11.8) 13.5 (4.5–103.4) <0.001
AJCC TNM stage, 7 th
I 43 (54.4%)    36 (45.6%)   
II 23 (29.1%)    25 (31.6%)   
III 9 (11.4%)    10 (12.7%)   
IV 4 (5.1%)    8 (10.1%)   
  1. Data are presented as means with standard deviation (SD) or numbers (%), unless otherwise indicated.